Syndax Pharmaceuticals Stock Falls Over 11% After Drug Trial Misses Endpoint

Syndax Pharmaceuticals (NASDAQ: SNDX) saw its stock price decline by over 11% on October 13, 2026, following the company's announcement that its drug axatilimab did not meet the primary endpoint in the Phase 2 MAXPIRe trial for idiopathic pulmonary fibrosis (IPF). Shares opened at approximately $14.61, down 11.72% from the previous day's close.

The 145-patient trial measured the annualized rate of decline in forced vital capacity (FVC), a key indicator of lung function. The results indicated no benefit for axatilimab on this primary measure. Syndax has stated it will not pursue further development of axatilimab for IPF, though its graft-versus-host disease (GVHD) programs remain active.

Following the announcement, legal firms have notified investors of pending investigations into potential securities law violations. Shareholders who experienced financial losses due to the decline in SNDX stock are encouraged to contact these firms for information regarding potential recovery options.

This outcome represents a setback for Syndax's IPF program. Previous statements from the company, including comments made during its fiscal Q4 2025 earnings call in February 2026, had expressed confidence in the trial's design and potential outcomes, making the reported results particularly disappointing.